Literature DB >> 19019299

New treatments for neuromuscular disease: optimism and obstacles.

Hanns Lochmüller, Robert C Griggs.   

Abstract

Entities:  

Mesh：

Year:  2008        PMID： 19019299      PMCID： PMC4514702          DOI： 10.1016/j.nurt.2008.08.010

Source DB:  PubMed          Journal:  Neurotherapeutics        ISSN： 1878-7479            Impact factor:   7.620


× No keyword cloud information.
  3 in total

Review 1.  Congenital myasthenic syndromes: spotlight on genetic defects of neuromuscular transmission.

Authors:  Juliane S Müller; Violeta Mihaylova; Angela Abicht; Hanns Lochmüller
Journal:  Expert Rev Mol Med       Date:  2007-08-09       Impact factor: 5.600

Review 2.  Current status of gene therapy for muscle diseases.

Authors:  Christian Thirion; Hanns Lochmüller
Journal:  Drug News Perspect       Date:  2007 Jul-Aug

3.  Effect of prednisone on protein metabolism in Duchenne dystrophy.

Authors:  Z Rifai; S Welle; R T Moxley; M Lorenson; R C Griggs
Journal:  Am J Physiol       Date:  1995-01
  3 in total
  1 in total

1.  Combined N-of-1 trials to investigate mexiletine in non-dystrophic myotonia using a Bayesian approach; study rationale and protocol.

Authors:  Bas C Stunnenberg; Willem Woertman; Joost Raaphorst; Jeffrey M Statland; Robert C Griggs; Janneke Timmermans; Christiaan G Saris; Bas J Schouwenberg; Hans M Groenewoud; Dick F Stegeman; Baziel G M van Engelen; Gea Drost; Gert Jan van der Wilt
Journal:  BMC Neurol       Date:  2015-03-25       Impact factor: 2.474
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.